Adagio Raises $336 Million to Support Development of COVID-19 Antibody Candidate

Adagio Therapeutics announced today it has completed a $336 million Series C financing round, which the company says will support the advancement of its lead coronavirus disease 2019 (COVID-19) monoclonal antibody candidate ADG20. The new financing round was led by RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.
Read more...

;